https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Validation of a Flow Cytometry Live Cell-Based Assay to Detect Myelin Oligodendrocyte Glycoprotein Antibodies for Clinical Diagnostics https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46794 Wed 30 Nov 2022 14:31:28 AEDT ]]> The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing-remitting multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39575 Wed 27 Jul 2022 14:43:55 AEST ]]> Patient-determined disease steps is not interchangeable with the Expanded Disease Status Scale in mild to moderate multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54397 Wed 21 Feb 2024 15:48:45 AEDT ]]> Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48348 Wed 14 Feb 2024 15:59:55 AEDT ]]> The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-Associated disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:55423 Tue 28 May 2024 14:56:42 AEST ]]> Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51306 Thu 31 Aug 2023 14:27:51 AEST ]]> Prediction of multiple sclerosis outcomes when switching to ocrelizumab https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46515 Thu 24 Nov 2022 15:50:23 AEDT ]]> Managing cognitive impairment and its impact in multiple sclerosis: An Australian multidisciplinary perspective https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52643 Thu 19 Oct 2023 15:18:30 AEDT ]]> Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51965 Mon 25 Sep 2023 08:53:21 AEST ]]> Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: a contemporary cohort study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41847 p = 0.010); but no differences in spontaneous abortions, term or preterm births. Conclusions: We report low pregnancy incidence rates, with increasing number of pregnancies conceived on DMT over the past 12-years. The median duration of DMT exposure in pregnancy was relatively short at one month.]]> Mon 15 Aug 2022 10:27:59 AEST ]]> Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> Longitudinal epidemiology of multiple sclerosis in Townsville, Queensland, Australia, 2012-2022 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54178 Mon 12 Feb 2024 13:11:52 AEDT ]]> Prediction of relapse activity when switching to cladribine for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51076 Fri 18 Aug 2023 09:03:23 AEST ]]>